Advanced Body Check
ETERNALAB TOKYO's advanced health screening is a precision program for subclinical conditions and chronic disease risk assessment. Using clinical-grade equipment and molecular analysis, we evaluate physiological status, metabolic function, inflammatory markers, and aging indicators to enable precise prevention and personalized treatment.
This is a regenerative medicine-oriented health management system supporting early detection, aging prevention, and enhanced repair capacity.
Comprehensive preventive screening encompasses advanced diagnostic approaches designed to evaluate disease risk at an early and often pre-symptomatic stage, forming the foundation of personalized health management and preventive medicine.
miRNA cancer screening analyzes microRNA expression patterns associated with tumor development and progression, providing molecular-level insights into potential oncological risk.
Liquid biopsy multi-cancer screening detects circulating biomarkers such as tumor-derived DNA, RNA, or extracellular vesicles in the bloodstream, enabling minimally invasive assessment of multiple cancer types simultaneously.
Cancer risk navigation integrates longitudinal data interpretation, genetic predisposition, and biomarker trends to construct an individualized risk profile, supporting dynamic monitoring and structured preventive strategies.
Comprehensive Preventive Screening
Comprehensive preventive screening encompasses advanced diagnostic approaches designed to evaluate disease risk at an early and often pre-symptomatic stage, forming the foundation of personalized health management and preventive medicine.
Comprehensive Preventive Screening
miRNA Cancer Early Detection
miRNA cancer screening analyzes microRNA expression patterns associated with tumor development and progression, providing molecular-level insights into potential oncological risk.
miRNA Cancer Early Detection
Liquid Biopsy Multi-Cancer Screening
Liquid biopsy multi-cancer screening detects circulating biomarkers such as tumor-derived DNA, RNA, or extracellular vesicles in the bloodstream, enabling minimally invasive assessment of multiple cancer types simultaneously.
Liquid Biopsy Multi-Cancer Screening
Cancer Risk Navigation
Cancer risk navigation integrates longitudinal data interpretation, genetic predisposition, and biomarker trends to construct an individualized risk profile, supporting dynamic monitoring and structured preventive strategies.
Cancer Risk Navigation
Biological Age Assessment
Comprehensive preventive screening encompasses a range of advanced diagnostic approaches designed to evaluate disease risk at an early and often pre-symptomatic stage. These include miRNA-based cancer early detection, liquid biopsy multi-cancer screening, and cancer risk navigation strategies.
miRNA cancer screening analyzes microRNA expression patterns associated with tumor development and progression, providing molecular-level insights into potential oncological risk. Liquid biopsy multi-cancer screening detects circulating biomarkers such as tumor-derived DNA, RNA, or extracellular vesicles in the bloodstream, enabling minimally invasive assessment of multiple cancer types simultaneously.
Cancer risk navigation integrates longitudinal data interpretation, genetic predisposition, and biomarker trends to construct an individualized risk profile. This allows for dynamic monitoring and structured preventive strategies aimed at optimizing early detection and long-term health management.
